Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today, we see march-in rights return to the headlines, ponder how Eli Lilly’s plan to hike list prices in Europe may play out, and more.

Trump administration puts focus on march-in rights

The Trump administration recently threatened to invoke a controversial provision of the Bayh-Dole Act to potentially seize and relicense Harvard University patents stemming from federally funded research, accusing the school of breaching disclosure and licensing rules. A letter from Commerce Secretary Howard Lutnick signaled a “march-in” review — a power never used before — which is being viewed by some as political retribution.

To read the rest of this story subscri

See Full Page